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Breast enlargement in Malawian males on the standard 
first-line antiretroviral therapy regimen: Case reports 
and review of the literature 
Case presentations
1. A 35-year-old man was referred to Zomba Central 
Hospital in June 2014 from a health center with a presenting 
complaint of  enlarged breasts. This had started gradually, 
approximately six months prior. He did not experience 
any pain or discharge from his nipples. He had no other 
complaints and felt generally healthy. In early 2013 he had 
been concomitantly diagnosed with pulmonary tuberculosis 
and HIV infection and was started on cotrimoxazole 
prophylaxis and antiretroviral therapy (ART) with tenofovir, 
lamivudine, and efavirenz, which is the standard first-line 
adult ART regimen, known in Malawi as regimen 5A. At 
that point, he had WHO clinical stage III HIV disease; a 
CD4 count was not done. There was no further relevant past 
medical history. He looked healthy and had normal vital signs. 
The rest of  the physical examination was normal except 
for bilateral, symmetrical, elastic, and concentric swelling 
of  the breasts, without discrete nodules, skin changes, 
or lymphadenopathy in the axillae and neck. There were 
no features of  lipodystrophy and no stigmata of  chronic 
liver disease. The genital examination was normal, without 
palpable abnormalities of  the normal-sized testes. Upon 
laboratory investigation, his CD4 count was 130 cells/µL 
and a full blood count was normal apart from the presence 
of  macrocytosis. Liver enzymes were unremarkable. 
2. In October 2014, we saw a 56-year-old male who presented 
with development of  painless bilateral breast enlargement. 
This had started in May 2014, followed by spontaneous 
regression and then subsequent worsening from August 
2014. The left breast was more conspicuously affected. He 
also mentioned experiencing weight loss but had no other 
symptoms. He was diagnosed with HIV infection in 2005 
and started on ART in 2008 due to a low CD4 count of  
83 cells/µL. While on his first ART regimen—stavudine, 
lamivudine, and nevirapine—he experienced progressive 
peripheral neuropathy and was eventually switched to a 
regimen of  zidovudine, lamivudine, and nevirapine, after 
which his CD4 count was 409 cells/µL and plasma HIV-1 
RNA was undetectable. Six months later, in January 2010, 
he developed severe anaemia, secondary to zidovudine, and 
his ART regimen was changed again, this time to tenofovir, 
lamivudine, and efavirenz (regimen 5A). He had no other 
significant past medical history and the only medications 
he used were cotrimoxazole prophylaxis and tenofovir, 
lamivudine, and efavirenz. Bilateral breast enlargement (left 
more than right, see Figure 1) was the only abnormality 
found on physical examination, with the same pertinent 
negative findings as in the first case presented in this report. 
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Discussion
Both patients had gynaecomastia, which is defined as a 
benign proliferation of  breast tissue in males. It has to be 
distinguished from pseudogynecomastia and lipomastia, 
which are both forms of  fat accumulation in the breasts. 
Lipomastia is part of  the lipodystrophy syndrome. 
Antiretroviral drugs that commonly cause lipomastia include 
stavudine, didanosine, and protease inhibitors. Breast 
palpation can help to distinguish fat accumulation in the 
breasts from true gynaecomastia.1 In gynaecomastia, typically 
a soft, elastic or firm disk-shaped mass, that is concentric 
with the nipple-areola, can be palpated with the patient lying 
flat on his back. Uncommonly, benign tumours and breast 
cancer can also cause breast enlargement in males. 
Once the presence of  gynaecomastia is established, a 
differential diagnosis of  its causes needs to be considered. 
There are two broad categories: physiological gynaecomastia 
(common) and pathological gynaecomastia (uncommon). 
Physiological gynaecomastia is self-limiting and occurs in 
newborns, adolescents, and the elderly. The pathological 
causes can be further divided up into three subcategories, 
namely testosterone deficiency, increased oestrogen 
production, and drug-induced breast enlargement. 
Testosterone deficiency can occur in HIV infection. Causes 
of  excess oestrogen include β-hCG-producing tumours 
(especially testicular cancers), chronic liver disease, and 
malnutrition. Drugs that can induce gynaecomastia and are 
commonly used in Malawi include ketoconazole, cimetidine, 
omeprazole, spironolactone, isoniazid, calcium channel 
blockers, ACE inhibitors, and antiretroviral drugs. If  the 
cause of  gynaecomastia remains unknown, it is classified as 
idiopathic. A comprehensive overview of  the pathological 
causes of  gynaecomastia is shown in Table 1.1-3
We conducted a PubMed search with the search terms 
HIV and gynaecomastia and located 71 publications, 
none being from Africa. The oldest case report was in an 
Figure 1: Gynaecomastia in patient 2
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HIV-infected patient in 1987, before the introduction of  
antiretroviral drugs.4 A French study noted the prevalence of  
gynaecomastia in patients on ART for more than two years to 
be 2.8%.5 In Switzerland, the incidence of  gynaecomastia in 
patients on ART was 2.3%. The first case series documenting 
efavirenz-associated gynaecomastia was published in 2001.6 
A case-control study from New York (n = 23) described an 
association between gynaecomastia and efavirenz.7 In Spain, 
a case-control study (n = 30) found an association with 
efavirenz, but also with didanosine and hypogonadism, with 
resolution occurring in 75% of  the cases.8 In a case series 
(n = 5) of  efavirenz-associated gynaecomastia, the onset of  
gynaecomastia occurred between 4 and 15 months after the 
start of  ART. Upon a change of  regimen, resolution was 
seen in all cases after several months.9 In vitro experiments 
have suggested that efavirenz activates oestrogen receptors 
in breast tissue,10 although subsequent experiments to 
confirm this finding have not yet been conducted. A 
systematic review concluded that the quality of  the evidence 
of  the association between gynaecomastia and antiretroviral 
drugs was moderate in general, being most convincing with 
efavirenz.11 We found one paper, from Nigeria, that was not 
included in PubMed, with six well-documented cases of  
efavirenz-associated gynaecomastia, of  which five resolved 
upon stopping efavirenz.12
The literature demonstrates that gynaecomastia is a rare but 
well-documented side effect of  efavirenz, but data from 
Malawi are lacking and only a single report exists from the 
whole of  Africa. The incidence, prevalence, and risk factors 
of  efavirenz-associated gynecomastia in Africans are thus 
unknown. Routine side effect monitoring of  ART in Malawi’s 
HIV programme strongly underreports the true prevalence 
of  toxicities. Although there are sections for side effects in 
electronic monitoring systems that are used in larger HIV 
clinics and on the paper master cards used in smaller HIV 
clinics, clinicians often do not report side effects unless 
they are planning a change in ART regimen.13 In addition, 
gynaecomastia is not explicitly listed as a side effect in routine 
monitoring and evaluation tools. Clinicians will therefore not 
be reminded that efavirenz causes gynaecomastia and may 
forget to screen patients for it during busy HIV clinics. Even 
if  clinicians do remember to screen for gynaecomastia, they 
will be unable to record it as a specific side effect. As a result, 
gynaecomastia does not appear in Malawi’s national ART 
statistics. Moreover, patients may not be educated on all the 
ART side effects and may not be aware that the gynaecomastia 
they experience is caused by their ART regimen. 
Genetic factors that differ between races and ethnic groups 
impact on drug toxicities.14 Extrapolation of  findings from 
Western settings may therefore lead to overestimation 
or underestimation of  side effects in Africans. Genetic 
polymorphisms, particularly in genes coding for cytochrome 
P450 2B6 and other liver enzymes involved in the metabolism 
of  efavirenz, are well-documented in African populations.15 
Some are known to lead to reduced efavirenz metabolism, 
higher drug levels, and more neurotoxicity, and could also 
be relevant for gynaecomastia occurring among men taking 
efavirenz.
After the introduction of  the new standardized first-line 
ART regimen 5A, which contains efavirenz, there were 
several case reports in the South East Health Zone of  
Malawi documenting gynaecomastia in patients who had 
changed from the previous to the new first-line regimen. 
Articles were published in Malawian newspapers and on 
websites describing it as common and debilitating, especially 
in the Mangochi district. This created some controversy 
and concerns arose that the media attention could affect 
male enrolment in HIV care. Although gynaecomastia is a 
fairly rare side effect that is not physically harmful for the 
individual, it may thus have a wider negative public health 
impact, as it could lead to reduced linkage to ART and 
increased non-adherence and defaulting from ART among 
men.
We propose practical measures to manage the issue of  
gynaecomastia in Malawi. At a public health level, we 
advise that gynaecomastia be included in standard pre-ART 
counselling. Males should receive the following information: 
gynaecomastia is a rare side effect of  ART that is not 
harmful but should be reported at an early stage, when a 
change of  ART regimen will have a better opportunity to 
promote spontaneous resolution. Secondly, gynaecomastia 
should be added to the electronic monitoring systems, 
master cards, and standard lists that nurses use for screening 
for and reporting of  side effects. On an individual level, 
if  a patient has developed breast swelling, it should first 
be established whether it is true gynaecomastia, mainly by 
physical examination. Then causes of  gynaecomastia other 
than efavirenz should be considered, such as testicular 
tumours, malnutrition, chronic liver disease, and other 
drugs. If  efavirenz is found to be the most likely cause of  
the gynaecomastia, reassurance and explanation should be 
offered with special attention to adherence, which may be at 
risk. A change of  ART regimen to tenofovir, lamivudine, and 
nevirapine (Malawi ART regimen 6A) should generally be 
made and resolution should be monitored over the course of  
several months. Surgery is only indicated in severe cases with 
severe cosmetic distress and when resolution does not occur 
in the months following change of  ART regimen. 
Both of  our patients changed from efavirenz to nevirapine. 
Six months later patient 1 reported some improvement and 
patient 2 said the situation was stable. They were satisfied 
with their condition despite the limited subjective and 
objective reduction of  the gynaecomastia. The incomplete 
resolution may be related to the advanced condition that 
had been present for several months before efavirenz was 
stopped. Alternatively, the gynaecomastia may have resulted 
from HIV-associated low testosterone levels.
Conclusion
Gynaecomastia is a well-recognized side effect of  efavirenz 
that has cosmetic and psychological consequences. Its 
incidence in Africans is currently unknown. Awareness by 
patients and clinicians and early management by substitution 
of  efavirenz with nevirapine can lead to resolution over 
months. Appropriate counselling should be offered to 
patients with gynaecomastia to avoid ART interruptions and 
non-adherence.
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2a. testosterone deficiency  
 
2b. increased oestrogen production 
 
2c. drugs   
Rare congenital syndromes (5α-reductase 
deficiency, Klinefelter syndrome, androgen 
insensitivity syndrome, congenital 
anorchia) 
  
Viral orchitis, HIV 
 






Neurological, granulomatous disease 
Testicular tumours 
 
Lung carcinoma  
 
Other β-hCG-producing tumours, such as 
renal cell cancer 
 
Adrenal disease and tumours 
 












enzyme inhibitors  
Antiretroviral agents  
Atorvastatin  

























































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
